At least one psilocybin-AUD mechanistic study (neurobehavioral) will publish peer-reviewed findings supporting rapid neuroplasticity by year-end.

A research team studying psilocybin as a treatment for alcohol use disorder will publish findings in a peer-reviewed journal showing exactly how the drug triggers rapid brain rewiring — what scientists call neuroplasticity. This matters because it moves psilocybin beyond 'it seems to work' toward 'here's the biological reason why.' That kind of evidence makes regulators, doctors, and insurers take the treatment more seriously.

The AUD mechanism trial is active and rapid-onset science is a hot publication lane. Mechanistic output is lower-risk than efficacy claims.